Saturday, April 20, 2024

Expanded Access to Anti-Obesity Medications in US Government Health Programs

Similar articles

The Centers for Medicare and Medicaid Services (CMS) has issued guidelines for Medicare Part D plans to cover anti-obesity medications for additional medical conditions, potentially extending access within U.S. government health programs. This coverage pertains to drugs that the FDA has approved for secondary indications, such as reducing the risk of major cardiovascular events, but not for treating obesity alone.

The change comes after the FDA expanded Wegovy’s label for cardiovascular event prevention, indicating a significant policy shift. However, coverage for obesity as a standalone condition is still not included, leading to ongoing congressional efforts to mandate it.

Pharmaceutical company Novo Nordisk and health policy experts see this as a positive development, although they expect prior authorization requirements to regulate usage for the approved additional conditions strictly. This modification allows for the inclusion of newly approved indications within existing contracts.

CMS’s Strategy on Anti-Obesity Medications and Healthcare Policy Shifts

CMS has highlighted the potential use of prior authorization to ensure appropriate drug use. The move is expected to expand access to anti-obesity medications within the U.S. government’s health programs, despite the restrictions on their use for obesity treatment alone.

The change represents a significant policy shift and follows the FDA’s decision to expand the label for Wegovy, an anti-obesity drug, for cardiovascular event prevention. However, the exclusion of coverage for obesity as a standalone condition has led to ongoing efforts in Congress to mandate it.

Anti-Obesity Medications

The Impact of CMS’s New Guidance on Anti-Obesity Medications Coverage and Health Policy

This policy adjustment is seen as a positive step by Novo Nordisk and health policy experts, despite expected prior authorization requirements to control usage for the approved additional conditions strictly. This allows for the incorporation of newly approved indications within existing contracts.

The CMS guidance for Medicare Part D plans to cover anti-obesity drugs for additional medical conditions represents a potential expansion of access within U.S. government health programs. This coverage extends to FDA-approved drugs for secondary indications, such as reducing the risk of severe cardiovascular events. However, despite the significant policy shift, coverage for obesity as a standalone condition remains excluded, prompting ongoing congressional efforts for its inclusion.

 

Resource: HealthEconomics, March 21, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article